GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
GSK PLC GSK shares inched down 0.55% to £13.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030.33. Supported ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
Below is Validea's guru fundamental report for GSK PLC (ADR) (GSK). Of the 22 guru strategies we follow, GSK rates highest using our Acquirer's Multiple Investor model based on the published ...
DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...
Hosted on MSN2d
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback